Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4] diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3

Journal of Medicinal Chemistry

Volumn 47, Issue 16, 2004, Pages 3934-3937

  Engler, Thomas A ^a   Henry, James R ^a   Malhotra, Sushant ^a   Cunningham, Brian ^a   Furness, Kelly ^a   Brozinick, Joseph ^a   Burkholder, Timothy P ^a   Clay, Michael P ^a   Clayton, Joshua ^a   Diefenbacher, Clive ^a   Hawkins, Eric ^a   Iversen, Philip W ^a   Li, Yihong ^a   Lindstrom, Terry D ^a   Marquart, Angela L ^a   McLean, Johnathan ^a   Mendel, David ^a   Misener, Elizabeth ^a   Briere, Daniel ^a   O'Toole, John C ^a   Porter, Warren J ^a   Queener, Steven ^a   Reel, Jon K ^a   Owens, Rebecca A ^a   Brier, Richard A ^a   Eessalu, Thomas E ^a   Wagner, Jill R ^a   Campbell, Robert M ^a   Vaughn, Renee ^a   more..

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 3 IMIDAZO[1,2 A]PYRIDIN 3 YL 4 (1,2,3,4 TETRAHYDRO [1,4]DIAZEPINO[6,7,1 HI]INDOL 7 YL)PYRROLE 2,5 DIONE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INSULIN; MALEIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; SIGNAL TRANSDUCTION; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMIDAZOLES; PYRIDINES; PYRROLES; RATS; RATS, ZUCKER;

EID: 3242766018     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049768a     Document Type: Article

References (33)

1. Amos, A. F.; McCarty, D. J.; Zimmet, P. The rising global burden of diabetes and its complications: estimations and projections to the year 2010. Diabetic Med. 1997, 14 (Suppl 5), S1-S85.
2. (a) Cohen, P.; Frame, S. The renaissance of GSK. Nat. Rev. Mol. Cell. Biol. 2001, 2, 769.
3. (b) Cohen, P.; Goedert, M. Nat. Rev. Drug. Disc. 2004, 3, 479.
4. Ali, A.; Hoeflich, K. P.; Woodgett, J. R. Glycogen Synthase Kinase-3: Properties, Functions, and Regulation. Chem. Rev. 2001 101, 2527.
5. Woodgett, J. R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9, 2431.
6. Cohen, P. Muscle glycogen synthase. The Enzymes; Academic Press: New York, 1986; Vol. XVII, p 461.
7. Cross, D. A. E.; Alessi, D. R.; Cohen, P.; Andjelkovich, M.; Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378, 785.
8. Nikoulina, S. E.; Ciaraldi, T. P.; Mudaliar, S.; Mohideen, P.; Cartet, L.; Henry R. R. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000, 49, 263.
9. (a) Wagman, A. S.; Johnson, K. W.; Bussiere, D. E. Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes. Curr. Pharm. Design, 2004, 10, 1.
10. (b) For recent papers with leading references, see (b) Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A.-L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. 2004, 47, 935.
11. (c) Kunick, C.; Lauenroth, K.; Leost, M.; Meijer, L.; Lemcke, T. I-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3β. Bioorg. Med. Chem. Lett. 2004, 14, 413.
12. Hers, I.; Tavare, J. M.; Denton, R. M. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 1999, 460, 433.
13. Coghlan, M. P.; Culbert, A. A.; Cross, D. A. E.; Corcoran, S. L.; Yates, J. W.; Pearce, N. J.; Rausch, O. L.; Murphy, G. J.; Carter, P. S.; Cox, L. R.; Mills, D.; Brown, M. J.; Haigh, D.; Ward, R. W.; Smith, D. G.; Murray, K. J.; Reith, A. D.; Holder, J. C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7, 793.
14. (a) Kuo, G.; Prouty, C.; DeAngelis, A.; Shen, L.; O'Neill, D. J.; Shah, C.; Connolly, P. J.; Murray, W. V.; Conway, B. R.; Cheung, P.; Westover, L.; Xu, J. Z.; Look, R. A.; Demarest, K. T.; Emanuel, S.; Middleton, S. A.; Jolliffe, L.; Beavers, M. P.; Chen, X. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3β inhibitors. J. Med. Chem. 2003, 46, 4021.
15. (b) Zhang, H.-C.; White, K. B.; Ye, H.; McComsey, D. F.; Derian, C. K.; Addao, M. F.; Andrade-Gordon, P.; Eckardt, A. J.; Conway, B. R.; Westover, L.; Xu, J. Z.; Look, R.; Demarest, K. T.; Emanuel, S.; Maryanoff, B. E. Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 2003, 13, 3049.
16. ZDF rat data for a structurally distinct series of GSK3 inhibitors has been reported. Ring, D. A.; Johnson, K. W.; Henriksen, E. J.; Nuss, J. M.; Goff, D.; Kinnick, T. R.; Ma, S. T.; Reeder, J. W.; Samuels, I.; Slabiak, T.; Wagman, A. S.; Hammond, M. W.; Harrison, S. D. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, 52, 588.
17. Moyer, M. P.; Shiurba, J. F.; Rapoport, H. Metal-Halogen exchange of bromoindoles. A route to substituted indoles. J. Org. Chem. 1986, 51, 5106.
18. The synthesis of 4 (R2 = H) has been reported. (a) Al-Awar, R. S.; Ray, J. E.; Hecker, K. A.; Joseph, S.; Huang, J.; Shih, C.; Brooks, H. B.; Spencer, C. D.; Watkins, S. A.; Schultz, R. M.; Considine, E. L.; Faul, M. M.; Sullivan, K. A.; Kolis, S. P.; Carr, M. A.; Zhang, F. Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors. Bioorg. Med. Chem. Lett. 2004, in press.
19. (b) Al-Awar, R. S.; Hecker, K. A.; Huang, J.; Sajan, J. Ray, J. E.; Waid, P. P. Preparation of maleimide and carbazole derivatives for the treatment of proliferative diseases. WO2001044235 A3.
20. Almirante, L.; Mugnaini, A.; Rugarli, P.; Gamba, A.; Zefelippo, E.; De Toma, N.; Murmann, W. Derivatives of imidazole. III. Synthesis and pharmacological activities of nitriles, amides, and carboxylic acid derivatives of imidazo[1,2-a]pyridine. J. Med. Chem. 1969, 12, 122.
21. (a) Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. A new, efficient method for the synthesis of bisindolylmaleimides. J. Org. Chem. 1998, 63, 6053.
22. (b) Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides. Tetrahedron Lett. 1999, 40, 1109.
23. Wall, M. E.; Wani, M. C.; Mansukh, C.; Nicholas, A. W.; Manikumar, G.; Tele, C.; Moore, L.; Truesdale, A.; Leitner, P.; Besterman, J. M. Plant antitumor agents. 30. Synthesis and activity of novel camptothecin analogues. J. Med. Chem. 1993, 36, 2689.
24. (a) Bartoli, G.; Palmieri, G.; Bosco, M.; Dalpozzo, R. The reaction of vinyl Grignard reagents with 2-substituted nitroarenes: A new approach to the synthesis of 7-substituted indoles. Tetrahedron Lett. 1989, 30, 2129.
25. (b) Bosco, M.; Dalpozzo, R.; Bartoli, G.; Palmieri, G.; Petrini, M. Mechanistic Studies on the Reaction of Nitro- and Nitrosoarenes with Vinyl Grignard Reagents. J. Chem. Soc., Perkin Trans. 2, 1991, 657.
26. (c) Dobson, D. R.; Gilmore, J.; Long, D. A. Synthesis of 7-formylindole using the Bartoli indole methodology. Synlett 1992, 79.
27. Fiol, C. J.; Williams, J. S.; Chou, C. H.; Wang, Q. M.; Roach, P. J.; Andrisani, O. M. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J. Biol. Chem. 1994, 269, 32187.
28. Wang, Q. M.; Roach, P. J.; Fiol, C. J. Use of a synthetic peptide as a selective substrate for glycogen synthase kinase-3. Anal. Biochem. 1994, 220, 397.
29. Takahashi, M.; Yasutake, K.; Tomizawa, K. Lithium inhibits neurite growth and Tau protein kinase I/glycogen synthase kinase-3β-dependent phosphorylation of juvenile Tau in cultured hippocampal neurons. J. Neurochemistry 1999, 73 (5), 2073.
30. 50 being dependent on enzyme concentration.
31. Cross reactivity with CDKs and PKCs is common for many, but not all, GSK-3 inhibitors. See refs 8b, 8c, and 11.
32. Mordes, J. P.; Rossini, A. A. Animal models of diabetes. Am. J. Med. 1981, 70, 353.
33. For comparison, the PPAR agonist rosiglitazone has an MED in the range of 1-3 mg/kg in the same ZDF rat assay.